Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2011

View Archived Issues

Anchor Therapeutics presents new chemokine CXCR4 receptor agonists

Clinical investigation of NPSP-558 for hypoparathyroidism updated

Novel glucocorticoid receptor modulators may have fewer side effects than steroids

Applied Genetic Technologies receives grant for X-linked retinoschisis gene therapy

Japanese MHLW adds fenofibrate tablets to NHI price list

GetGoal-F1 results add to phase III data on lixisenatide in type 2 diabetes

Pilot trial investigates new protocol for treatment of severe pemphigus

Phase I data on Ad26.ENVA.01 in HAdV-26-seronegative and -seropositive HIV-1-uninfected adults

Randomized trial assesses estetrol in women with ER-positive early-stage breast cancer

Korean university synthesizes new PPAR-beta/delta ligands

New Mnk inhibitors patented by Boehringer Ingelheim

Spanish research teams disclose new anticancer cyclic peptides

New recombinant PEGylated FVIII molecules prepared at Novo Nordisk

Theraclone Sciences begins phase I trial of TCN-032

BMS and Ambrx establish partnership for biologics

Biofrontera submits final documents to address BF-200 ALA NDA

Zymeworks secures financing for antibody technology and pipeline programs

Acetylon Pharmaceuticals initiates phase I/IIa ACY-1215 study

ACT clear to conduct phase I/II stem cell therapy trial in U.K.

EMA committee recommends extending approval of Levemir

Shire provides update on ProAmatine in U.S.

RXi acquires worldwide license for vaccine candidate targeting gynecological cancers

EMA confirms positive benefit-to-risk balance for Multaq

ImmunoGen submits IND for anticancer candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...